HIV Drugs and Injectables Market Report 2024-2034

HIV Drugs and Injectables Market Report 2024-2034

The HIV Drugs & Injectables Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Demand for Newer Drugs Poses a Challenge for Generic Manufacturers

The patients undergoing HIV treatment regimens prefer to take newly launched drugs over the previous blockbuster HIV drugs or generic drugs owing to fact that new drugs tend to be safer with fewer side-effects and are less likely to develop early drug resistance due to which very limited generic drug manufacturers are operating in this sector. The three major players of generic HIV drugs market include Aurobindo, Cipla and Mylan. These companies are capable of manufacturing a wide range of generics and can generate profits despite decline in demand, while it becomes difficult for small generic manufacturers. Thus, fast changing drug science and new drug launches make certain drugs obsolete for example in recent years few of the blockbuster drugs such as Crixivan (indinavir), Invirase (saquinavir), Rescriptor (delaviridine), Videx (didanosine) Viracept (nelfinavir), and Zerit (stavudine) have all been removed from the market. Moreover, some of the innovator companies are also signing pay for delay pact with the generic firms to delay the launch of generics in the market and retain their monopolistic status.

Lack of Trained Staff and Infrastructural Facilities

There has been a growing demand for LAI for HIV treatment and PrEP however pressing needs pertaining training, staffing, storage and refrigeration in certain cases have been a major hurdle for implementing LA HIV regimens. Private groups do not staff nurses and might need to hire nurses and storage systems for administration of these injectables. Role of pharmacies and HIV care systems through its existing networks needs to be considered for widescale deployment of LAIs. Post pandemic there has been a rise in administration of wide variety of medication classes by the pharmacy staff. These pharmacies and community-based drugstores can be commissioned to delivery of LAI by pharmacy staff, while policymakers can incentivize these services offered at these places. Moreover, changes in electronic health record systems, restructuring of the clinic visits needs to be spanned out for effective and smooth implementation of LAI injectables for HIV.

What Questions Should You Ask before Buying a Market Research Report?

• How is the HIV Drugs & Injectables market evolving?
• What is driving and restraining the HIV Drugs & Injectables market?
• How will each HIV Drugs & Injectables submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
• How will the market shares for each HIV Drugs & Injectables submarket develop from 2024 to 2034?
• What will be the main driver for the overall market from 2024 to 2034?
• Will leading HIV Drugs & Injectables markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
• Who are the leading players and what are their prospects over the forecast period?
• What are the HIV Drugs & Injectables projects for these leading companies?
• How will the industry evolve during the period between 2024 and 2034? What are the implications of HIV Drugs & Injectables projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the HIV Drugs & Injectables market?
• Where is the HIV Drugs & Injectables market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the HIV Drugs & Injectables market today, and over the next 10 years:

• Our This 288-page report provides 118 tables, 188 charts exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

Forecasts to 2034 and other analyses reveal commercial prospects

• In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising HIV Drugs & Injectables prices and recent developments.

Segments Covered in the Report

Drug Class

• Combination Therapies (Inclu. InSTI)
• Nucleoside and Non-Nucleoside RTIs
• Protease Inhibitors

Oral Drugs

• Biktarvy
• Complera
• Delstrigo
• Dovato
• Genvoya
• Juluca
• Odefsey
• Stribild
• Symtuza
• Triumeq
• Descovy
• Truvada
• Edurant
• Pilfreto
• Rukobia
• Prezista
• Isentress
• Tivicay

Long-Acting Injectables

• Cabuneva
• Sunlenca
• Trogarzo
• Enfuvirtide

Pre-Exposure Prophylaxis Injectables

• Apretude
• Lencapavir

Drug Type

• Branded
• Generics

Distribution Channels

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:

North America

• U.S.
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

Latin America

• Brazil
• Mexico
• Rest of Latin America

MEA

• GCC
• South Africa
• Rest of MEA

The report also includes profiles for some of the leading companies in the HIV Drugs & Injectables Market, 2024 to 2034, with a focus on this segment of these companies’ operations.

Leading companies profiled in the report

• AbbVie Inc.
• Bristol Myers Squibb
• Frontier Biotechnologies
• Gilead Sciences
• J&J Innovation Medicine
• Merck KGaA
• Teva Pharmaceuticals
• Theratechnologies
• ViiV Healthcare (a GSK Company)

Overall world revenue for HIV Drugs & Injectables Market, 2024 to 2034 in terms of value the market will surpass US$35 billion in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the HIV Drugs & Injectables Market, 2024 to 2034 report help you?

In summary, our 280+ page report provides you with the following knowledge:

• Revenue forecasts to 2034 for HIV Drugs & Injectables Market, 2024 to 2034, with forecasts for drug class, oral drug, long acting injectables, PrEP injectables, drug type and distribution channels, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2034 for five regional and 20 key national markets – See forecasts for the HIV Drugs & Injectables Market, 2024 to 2034 in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the U.S., Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market – including company profiles for 9 of the major companies involved in the HIV Drugs & Injectables Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the HIV Drugs & Injectables Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.